SIRT1 and cancer: Unfortunately, our analysis failed to conclude the significance between increased Sirt1 expression and relapse-free survival (RFS, n = 6, HR: 1.58, 95% CI: [0.97, 2.60], P = 0.07, I2 = 84%, Supplementary Figure 6), disease-free survival (DFS, n = 9, HR: 1.23, 95% CI: [0.88, 1.73], P = 0.22, I2 = 71%, Supplementary Figure 7) or cancer-specific survival (CSS, n = 3, HR: 1.40, 95% CI: [0.60, 3.30], P = 0.44, I2 = 89%, Supplementary Figure 8) among solid malignancies.